Looking for the best immune‐checkpoint inhibitor in pre‐treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab
Francesco Passiglia; Antonio Galvano; Sergio Rizzo; Lorena Incorvaia; Angela Listì; Viviana Bazan; Antonio Russo
Author Information: Department of Surgical
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.